CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
about
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response.Serum CA19-9 in patients with solid pancreatic mass.Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancerImportance of performance status for treatment outcome in advanced pancreatic cancer.At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatment.Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiationEstimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapySurvival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study.Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.The prognostic and predictive value of serum CA19.9 in pancreatic cancerCA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancerClinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution.Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancerGlycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteinsPhase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experienceThe prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma.Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases.Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered.Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom ScoreCA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.Serum CA 19-9 and risk of incident diabetes in middle-aged and elderly Chinese: a prospective cohort study.S-1 plus CIK as second-line treatment for advanced pancreatic cancer.A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placeboEarly decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumorsThe clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.Chemically-blocked antibody microarray for multiplexed high-throughput profiling of specific protein glycosylation in complex samples.Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer.A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer.Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms.
P2860
Q33394190-4FC947C8-5E7C-4055-B42D-B83EF657B697Q33443909-07765B44-BC27-4D01-87D0-35FF816A09BDQ33596555-723318AD-61DD-41AB-9B2F-AD4D4D3ABE3BQ33626863-69616153-3170-46CA-A7D5-96EE34819ACFQ33728198-2BF30CA7-013C-471C-854B-F060C32D7EA3Q33787820-96499D59-06F7-4076-9E47-F712465A22CBQ33927576-A11F4664-4E68-4BF2-8AFE-D64B576FEDD6Q33928253-3F6310BE-A3AE-4A37-AD81-1477785A48DBQ34344188-16EE67F5-94A9-4910-A0BB-32E05F53B4D7Q34566049-2EC5F0F0-1792-4783-8D96-6C0364ADCCC9Q34632818-FCDF9A21-B4C2-4F1B-B1D4-EE1EE934AB68Q34635104-239E5E75-90ED-457C-9C83-89573D2CB436Q34646563-1C54C99C-D59F-40CF-A562-759ABD5F91E3Q34665177-81383BFA-3E94-48E5-9F85-7C73E563D329Q34669394-0E5153BB-A633-4C68-B7A1-6A14DB433DDEQ35046670-0743793F-16FE-495C-9C43-2F1E9AA9AB74Q35872109-5E7A8BA2-9B58-484C-AE09-7B4E4E810A4FQ36064780-2725C43A-67BA-4C3D-A1F6-862FBD9E434EQ36089872-B6ADAB2B-3696-457F-8836-3352FCFA452AQ36136045-3F31B78A-03A3-48A8-8548-4D1FA4FBC681Q36191929-E4A206C4-FB74-40C4-A3E3-DA914F0EA909Q36610981-7F8CCFB5-2712-43DB-9DF6-688E79FEDD27Q36614087-B0B47325-1D9E-498F-A1AC-FE4CC1856750Q36937026-C0EFBFDF-91A2-436F-83F6-7F54EF722480Q37092146-2835200E-D91B-4D21-99CF-10F51B1789ABQ37350330-A890F011-58AE-429B-80C5-925867EA0958Q37398718-27FE0F10-E7F1-483F-9911-99F2ED13BD57Q37400577-5AEE0587-61F4-46D6-A2DD-7ED58EEC7859Q38018315-4556BAAE-2972-4998-86B1-938FF5FD4317Q38021384-C3C1A4EC-D64D-4AAD-B486-4DE2C613B384Q39225299-9E2597C6-F6BB-45F7-8C59-A74C284935A1Q40231668-456BBF04-67B0-48CD-97C3-34331189FD3FQ41159918-579A5225-2050-49B8-B9D2-548F4A77CAE2Q41506388-BE364ECE-4DCB-4057-8C87-1779AC003EF7Q42018828-9B595A39-0CCD-4198-AD84-66F587BADD7BQ42238114-1F812207-C184-4826-BAA2-53913917EF5BQ42434545-22C2117F-133A-4622-ABE5-054CC8E13EA2Q42985641-C51DE61D-D12E-494B-BAD3-18457C6C814EQ43857212-972085FE-4FCC-4782-B254-2DC54AF78480Q43964344-9AACB1A6-6096-4A10-B51A-0E9195C64C18
P2860
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
CA19-9 as a prognostic factor ...... mplication for clinical trials
@ast
CA19-9 as a prognostic factor ...... mplication for clinical trials
@en
type
label
CA19-9 as a prognostic factor ...... mplication for clinical trials
@ast
CA19-9 as a prognostic factor ...... mplication for clinical trials
@en
prefLabel
CA19-9 as a prognostic factor ...... mplication for clinical trials
@ast
CA19-9 as a prognostic factor ...... mplication for clinical trials
@en
P2093
P2860
P356
P1476
CA19-9 as a prognostic factor ...... mplication for clinical trials
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602760
P407
P577
2005-10-01T00:00:00Z